Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders

Journal of Clinical Psychiatry

Volumn 60, Issue 5, 1999, Pages 292-298

  McManus, Dennis Q ^b   Arvanitis, Lisa A ^a   Kowalcyk, Barbara B ^a  

^a ASTRAZENECA   (United Kingdom)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; CHLORAL HYDRATE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIHEXYPHENIDYL;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; GERIATRIC DISORDER; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SOMNOLENCE; VERTIGO;

EID: 0032994222     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0504     Document Type: Article

References (34)

1. Malmgren R. Epidemiology of aging. In: Coffey CE, Cummings JL, eds. Textbook of Geriatric Psychiatry. Washington, DC: American Psychiatric Press; 1994:16-33
2. Lebowitz BD, Cohen GD. Introduction: older Americans and their illnesses. In: Salzman C, ed. Clinical Geriatric Psychiatry. 2nd ed. Baltimore, Md: Williams & Wilkins; 1992:3-14
3. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiological evidence suggesting misuse. Am J Public Health 1980;70:485-491
4. Pollock BG, Mulsant BH. Antipsychotics in older patients: a safety perspective. Drugs Aging 1995;6:312-323
5. Zaleon CR, Guthrie SK. Antipsychotic drug use in older adults. Am J Hosp Pharm 1994;51:2917-2943
6. Goldberg PB, Roberts J. Pharmacologic basis for developing rational drug regimens for elderly patients. Med Clin North Am 1983;67:315-331
7. Maletta GJ. Use of antipsychotic medication in the elderly. Annu Rev Gerontol Geriatr 1984;4:175-220
8. Gregory C, McKenna P. Pharmacological management of schizophrenia in older patients. Drugs Aging 1994;5:254-262
9. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia incidence and risk factors. J Clin Psychopharmacol 1988;8(4 suppl):52-56
10. Wilson JA, MacLennan WJ. Review: drug induced parkinsonism in elderly patients. Age Ageing 1989;18:208-210
11. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992;62:51-70
12. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
13. Schuster P, Gabriel E, Kufferle B. Reversal by physostigmine of clozapine induced delirium. Clin Toxicol 1997;10:437-441
14. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
15. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
16. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-292
17. Goldstein JM, Litwin LC, Sutton EB, et al. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:293-298
18. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology (Berl) 1993;112:299-307
19. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic: review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Rev 1995;1:50-73
20. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
21. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
22. Casey DE. "Seroquel" (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996;5:939-957
23. Goldstein JM, Arvanitis LA. "Seroquel" (quetiapine), a promising new antipsychotic agent: overview of safety and tolerability [abstract]. Schizophr Res 1997;24:197
24. Seroquel [package insert]. Wilmington, Del: Zeneca Pharmaceuticals; 1997
25. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
26. Hamner MB, Arvanitis LA, Miller BG. Plasma prolactin in schizophrenia subjects treated with Seroquel. Psychopharmacol Bull 1996;32:107-110
27. Wong J, Ewing BJ, Jaskiw G, et al. Multiple-dose pharmacokinetics of "Seroquel" (quetiapine) in elderly psychotic patients [abstract]. Schizophr Res 1997;24:199-200
28. Wong JYW, Ewing BJ, Fabre LF, et al. Multiple-dose pharmacokinetics of "Seroquel" (quetiapine) in schizophrenic men and women [abstract]. Schizophr Res 1997;24:200
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
30. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45(suppl 212):11-19
31. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
32. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
34. Hellewell JSE, Cameron Hands D, McKellar J. "Seroquel": an effective atypical antipsychotic with no greater EPS than placebo across the full dose range [abstract]. Schizophr Res 1998;29:154